Amarin Corporation PLC
AMRN Healthcare Drug Manufacturers General
Amarin Corporation PLC’s revenue for fiscal 2025 (year ended December 2025) was $213.6 million, down 6.55% from fiscal 2024. In the quarter to June 2026, revenue fell 42.0%, EPS grew 45.8% and free cash flow fell 60.2%, each against the same quarter a year earlier.
Follow AMRN
Amarin Corporation PLC (AMRN) EV/Sales
As of 16 October 2026, Amarin Corporation PLC (AMRN) trades at a EV/Sales of −0.3×. Over the past ten years it has ranged from −0.5× (March 2025) to 33.2× (November 2018); the current reading is higher than 2% of that period. That is below the Drug Manufacturers General industry median of 4.0× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | −0.3× | — |
| FY2023 | 0.2× | (61.18%) |
| FY2022 | 0.5× | (67.19%) |
| FY2021 | 1.5× | (31.74%) |
| FY2020 | 2.2× | (85.70%) |
| FY2019 | 15.7× | (7.03%) |
| FY2018 | 16.9× | 156.00% |
| FY2017 | 6.6× | 27.78% |
| FY2016 | 5.2× | (11.40%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.2× | 210.11% |
| Mar 2026 | 0.1× | 151.23% |
| Dec 2025 | 0.0× | (92.29%) |
| Sep 2025 | 0.3× | 25.19% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AMRN Amarin Corporation PLC | −0.3× |
| MDCX Medicus Pharma Ltd compare | n/m |
| NSRX Nasus Pharma Ltd. compare | n/m |
| MIRA MIRA Pharmaceuticals, Inc. compare | n/m |
| GRFS Grifols, S.A. compare | 1.8× |
| OGN Organon & Co. compare | 1.8× |
| SNY Sanofi compare | 2.0× |
| SCLX Scilex Holding Company compare | 3.2× |
| BIIB Biogen Inc. compare | 4.0× |
| Drug Manufacturers General industry median | 4.0× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)